US 12,435,159 B2
Anti-human GRP94 antibodies and uses
Valery Krizhanovsky, Rehovot (IL); and Yossi Ovadya, Rehovot (IL)
Assigned to YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL)
Filed by YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL)
Filed on Dec. 7, 2022, as Appl. No. 18/062,601.
Application 18/062,601 is a continuation in part of application No. PCT/IL2021/050678, filed on Jun. 7, 2021.
Claims priority of application No. 275186 (IL), filed on Jun. 7, 2020.
Prior Publication US 2023/0094083 A1, Mar. 30, 2023
Int. Cl. C07K 16/44 (2006.01); A61K 39/00 (2006.01); A61P 43/00 (2006.01)
CPC C07K 16/44 (2013.01) [A61P 43/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01)] 13 Claims
 
1. An isolated anti-Grp94 antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein said antibody comprises:
(a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 6, the an HCDR2 comprising the amino acid sequence of SEQ ID NO:7, an HCDR3 comprising the amino acid sequence of SEQ ID NO:8, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 14, an LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and an LCDR3 comprising-comprises the amino acid sequence of SEQ ID NO: 16;
(b) an HCDR1 comprising the amino acid sequence of SEQ ID NO:6, an HCDR2 comprising the amino acid sequence of SEQ ID NO:7, an HCDR3 comprising the amino acid sequence of SEQ ID NO:20, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 14, an LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16;
(c) an HCDR1 comprising-comprises the amino acid sequence of SEQ ID NO:29, an HCDR2 comprising the amino acid sequence of SEQ ID NO:30, the an HCDR3 comprising the amino acid sequence of SEQ ID NO:31, the an LCDR1 comprising the amino acid sequence of SEQ ID NO: 37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:38, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:39; or
(d) a VH comprising the amino acid sequence of SEQ ID NO:41 and a VL comprising the amino acid sequence of SEQ ID NO:43.